JP2006515168A5

JP2006515168A5 -

Download PDF

Info

Publication number: JP2006515168A5
Authority: JP; Japan
Prior art keywords: xaa; composition; catalase; sequence; modified
Prior art date: 2003-10-30
Legal status : Pending

Application number

JP2004550263A

Other languages

English (en)

Japanese (ja)

Other versions

JP2006515168A (ja

Filing date

2003-10-30

Publication date

2010-09-16

2003-10-30 Application filed filed Critical

2003-10-30 Priority claimed from PCT/US2003/034512 external-priority patent/WO2004042011A2/en

2006-05-25 Publication of JP2006515168A publication Critical patent/JP2006515168A/ja

2010-09-16 Publication of JP2006515168A5 publication Critical patent/JP2006515168A5/ja

Status Pending legal-status Critical Current

Links

210000004027 cell Anatomy 0.000 claims description 259
108010053835 Catalase Proteins 0.000 claims description 257
102000016938 Catalase Human genes 0.000 claims description 256
108090000765 processed proteins & peptides Proteins 0.000 claims description 126
210000002824 peroxisome Anatomy 0.000 claims description 125
239000000203 mixture Substances 0.000 claims description 105
102000004196 processed proteins & peptides Human genes 0.000 claims description 86
229920001184 polypeptide Polymers 0.000 claims description 81
238000000034 method Methods 0.000 claims description 63
108010085186 Peroxisomal Targeting Signals Proteins 0.000 claims description 52
230000014509 gene expression Effects 0.000 claims description 30
230000008685 targeting Effects 0.000 claims description 25
150000001413 amino acids Chemical class 0.000 claims description 21
238000006467 substitution reaction Methods 0.000 claims description 20
102000040430 polynucleotide Human genes 0.000 claims description 19
108091033319 polynucleotide Proteins 0.000 claims description 19
239000002157 polynucleotide Substances 0.000 claims description 19
241001465754 Metazoa Species 0.000 claims description 17
239000002502 liposome Substances 0.000 claims description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
101000715499 Homo sapiens Catalase Proteins 0.000 claims description 14
239000012528 membrane Substances 0.000 claims description 14
201000010099 disease Diseases 0.000 claims description 13
102000045501 human CAT Human genes 0.000 claims description 13
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 12
239000002773 nucleotide Substances 0.000 claims description 11
125000003729 nucleotide group Chemical group 0.000 claims description 11
210000000130 stem cell Anatomy 0.000 claims description 11
238000000338 in vitro Methods 0.000 claims description 10
230000005945 translocation Effects 0.000 claims description 10
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims description 9
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims description 9
125000003275 alpha amino acid group Chemical group 0.000 claims description 9
230000002209 hydrophobic effect Effects 0.000 claims description 9
230000001225 therapeutic effect Effects 0.000 claims description 9
125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 claims description 8
238000001727 in vivo Methods 0.000 claims description 8
108091026890 Coding region Proteins 0.000 claims description 7
230000003834 intracellular effect Effects 0.000 claims description 7
150000007523 nucleic acids Chemical class 0.000 claims description 7
MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 7
108010043655 penetratin Proteins 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 claims description 6
108010088535 Pep-1 peptide Proteins 0.000 claims description 6
101710192266 Tegument protein VP22 Proteins 0.000 claims description 6
102000039446 nucleic acids Human genes 0.000 claims description 6
108020004707 nucleic acids Proteins 0.000 claims description 6
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 5
230000002441 reversible effect Effects 0.000 claims description 5
125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims description 4
125000000539 amino acid group Chemical group 0.000 claims description 4
208000015122 neurodegenerative disease Diseases 0.000 claims description 4
125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 claims description 3
125000002061 L-isoleucyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
102220582112 Putative uncharacterized protein FER1L6-AS1_W48F_mutation Human genes 0.000 claims description 3
241000700584 Simplexvirus Species 0.000 claims description 3
230000004048 modification Effects 0.000 claims description 3
238000012986 modification Methods 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
210000001539 phagocyte Anatomy 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
241001529453 unidentified herpesvirus Species 0.000 claims description 3
125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
206010063837 Reperfusion injury Diseases 0.000 claims description 2
238000011161 development Methods 0.000 claims description 2
208000017520 skin disease Diseases 0.000 claims description 2
238000011200 topical administration Methods 0.000 claims description 2
230000000302 ischemic effect Effects 0.000 claims 2
208000006784 Cutaneous Fistula Diseases 0.000 claims 1
230000003902 lesion Effects 0.000 claims 1
108090000623 proteins and genes Proteins 0.000 description 105
102000004169 proteins and genes Human genes 0.000 description 96
235000018102 proteins Nutrition 0.000 description 93
238000012546 transfer Methods 0.000 description 66
102000004190 Enzymes Human genes 0.000 description 59
108090000790 Enzymes Proteins 0.000 description 59
229940088598 enzyme Drugs 0.000 description 59
101000987688 Arabidopsis thaliana Peroxisome biogenesis protein 5 Proteins 0.000 description 54
210000003463 organelle Anatomy 0.000 description 47
GUGNSJAORJLKGP-UHFFFAOYSA-K sodium 8-methoxypyrene-1,3,6-trisulfonate Chemical compound [Na+].[Na+].[Na+].C1=C2C(OC)=CC(S([O-])(=O)=O)=C(C=C3)C2=C2C3=C(S([O-])(=O)=O)C=C(S([O-])(=O)=O)C2=C1 GUGNSJAORJLKGP-UHFFFAOYSA-K 0.000 description 39
101100465559 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PRE7 gene Proteins 0.000 description 36
101150076896 pts1 gene Proteins 0.000 description 36
230000000694 effects Effects 0.000 description 34
239000003642 reactive oxygen metabolite Substances 0.000 description 33
230000032683 aging Effects 0.000 description 31
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 23
108090001008 Avidin Proteins 0.000 description 23
230000027455 binding Effects 0.000 description 23
230000000858 peroxisomal effect Effects 0.000 description 23
235000001014 amino acid Nutrition 0.000 description 21
150000001875 compounds Chemical class 0.000 description 21
210000005260 human cell Anatomy 0.000 description 21
238000002474 experimental method Methods 0.000 description 20
239000005089 Luciferase Substances 0.000 description 17
210000002950 fibroblast Anatomy 0.000 description 17
-1 polyoxyethylene mono laurate Polymers 0.000 description 17
108060001084 Luciferase Proteins 0.000 description 16
230000035508 accumulation Effects 0.000 description 16
238000009825 accumulation Methods 0.000 description 16
230000001413 cellular effect Effects 0.000 description 16
238000010361 transduction Methods 0.000 description 16
230000026683 transduction Effects 0.000 description 16
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
239000012634 fragment Substances 0.000 description 15
108020003175 receptors Proteins 0.000 description 15
102000005962 receptors Human genes 0.000 description 15
239000003963 antioxidant agent Substances 0.000 description 14
230000002829 reductive effect Effects 0.000 description 14
238000003556 assay Methods 0.000 description 13
210000003743 erythrocyte Anatomy 0.000 description 13
230000006870 function Effects 0.000 description 13
230000001965 increasing effect Effects 0.000 description 13
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
229960002685 biotin Drugs 0.000 description 12
210000000172 cytosol Anatomy 0.000 description 12
230000008676 import Effects 0.000 description 12
239000003446 ligand Substances 0.000 description 12
239000000758 substrate Substances 0.000 description 12
210000001519 tissue Anatomy 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
235000006708 antioxidants Nutrition 0.000 description 11
235000020958 biotin Nutrition 0.000 description 11
239000011616 biotin Substances 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 11
230000000699 topical effect Effects 0.000 description 11
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
238000013459 approach Methods 0.000 description 10
210000004899 c-terminal region Anatomy 0.000 description 10
230000001771 impaired effect Effects 0.000 description 10
239000003921 oil Substances 0.000 description 10
235000019198 oils Nutrition 0.000 description 10
108030002458 peroxiredoxin Proteins 0.000 description 10
230000008569 process Effects 0.000 description 10
239000013598 vector Substances 0.000 description 10
238000002965 ELISA Methods 0.000 description 9
101000913652 Mus musculus Fibronectin type III domain-containing protein 5 Proteins 0.000 description 9
102000007456 Peroxiredoxin Human genes 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000000872 buffer Substances 0.000 description 9
238000005516 engineering process Methods 0.000 description 9
239000000463 material Substances 0.000 description 9
210000003491 skin Anatomy 0.000 description 9
239000000243 solution Substances 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
108091005804 Peptidases Proteins 0.000 description 8
102000035195 Peptidases Human genes 0.000 description 8
102000009913 Peroxisomal Targeting Signal 2 Receptor Human genes 0.000 description 8
108010077056 Peroxisomal Targeting Signal 2 Receptor Proteins 0.000 description 8
239000002537 cosmetic Substances 0.000 description 8
230000006378 damage Effects 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 8
239000000816 peptidomimetic Substances 0.000 description 8
108091003079 Bovine Serum Albumin Proteins 0.000 description 7
239000004365 Protease Substances 0.000 description 7
230000009471 action Effects 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
235000014113 dietary fatty acids Nutrition 0.000 description 7
239000000194 fatty acid Substances 0.000 description 7
229930195729 fatty acid Natural products 0.000 description 7
108020001507 fusion proteins Proteins 0.000 description 7
102000037865 fusion proteins Human genes 0.000 description 7
239000000499 gel Substances 0.000 description 7
239000011521 glass Substances 0.000 description 7
239000005090 green fluorescent protein Substances 0.000 description 7
239000007788 liquid Substances 0.000 description 7
241000894007 species Species 0.000 description 7
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 6
206010028980 Neoplasm Diseases 0.000 description 6
239000002253 acid Substances 0.000 description 6
229940098773 bovine serum albumin Drugs 0.000 description 6
230000032677 cell aging Effects 0.000 description 6
210000000170 cell membrane Anatomy 0.000 description 6
230000008859 change Effects 0.000 description 6
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
239000006071 cream Substances 0.000 description 6
230000001086 cytosolic effect Effects 0.000 description 6
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 6
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
230000009931 harmful effect Effects 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
230000003993 interaction Effects 0.000 description 6
150000002632 lipids Chemical class 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
238000004445 quantitative analysis Methods 0.000 description 6
230000009467 reduction Effects 0.000 description 6
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
108010063907 Glutathione Reductase Proteins 0.000 description 5
102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 5
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
239000000020 Nitrocellulose Substances 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
102000004316 Oxidoreductases Human genes 0.000 description 5
108090000854 Oxidoreductases Proteins 0.000 description 5
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
229920004890 Triton X-100 Polymers 0.000 description 5
239000013504 Triton X-100 Substances 0.000 description 5
239000013543 active substance Substances 0.000 description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
239000000969 carrier Substances 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
238000000576 coating method Methods 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000007547 defect Effects 0.000 description 5
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000000839 emulsion Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000010166 immunofluorescence Methods 0.000 description 5
238000000520 microinjection Methods 0.000 description 5
229920001220 nitrocellulos Polymers 0.000 description 5
210000000056 organ Anatomy 0.000 description 5
230000036542 oxidative stress Effects 0.000 description 5
229910052760 oxygen Inorganic materials 0.000 description 5
239000001301 oxygen Substances 0.000 description 5
239000012071 phase Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
239000000843 powder Substances 0.000 description 5
235000019419 proteases Nutrition 0.000 description 5
150000003254 radicals Chemical class 0.000 description 5
230000006697 redox regulation Effects 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000010186 staining Methods 0.000 description 5
238000001890 transfection Methods 0.000 description 5
241000283707 Capra Species 0.000 description 4
108020004705 Codon Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
102000006587 Glutathione peroxidase Human genes 0.000 description 4
108700016172 Glutathione peroxidases Proteins 0.000 description 4
206010021143 Hypoxia Diseases 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000004480 active ingredient Substances 0.000 description 4
239000000654 additive Substances 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000003078 antioxidant effect Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000011248 coating agent Substances 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
230000002255 enzymatic effect Effects 0.000 description 4
150000004665 fatty acids Chemical class 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
230000036541 health Effects 0.000 description 4
238000003119 immunoblot Methods 0.000 description 4
230000001976 improved effect Effects 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
230000007246 mechanism Effects 0.000 description 4
238000007254 oxidation reaction Methods 0.000 description 4
150000002978 peroxides Chemical class 0.000 description 4
229920005862 polyol Polymers 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000002562 thickening agent Substances 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
102100026189 Beta-galactosidase Human genes 0.000 description 3
108010067770 Endopeptidase K Proteins 0.000 description 3
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 3
101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 3
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
102100029139 Peroxiredoxin-1 Human genes 0.000 description 3
102100034768 Peroxiredoxin-4 Human genes 0.000 description 3
102000003743 Relaxin Human genes 0.000 description 3
108090000103 Relaxin Proteins 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
229920002125 Sokalan® Polymers 0.000 description 3
102000019197 Superoxide Dismutase Human genes 0.000 description 3
108010012715 Superoxide dismutase Proteins 0.000 description 3
102100034769 Thioredoxin-dependent peroxide reductase, mitochondrial Human genes 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
108010005774 beta-Galactosidase Proteins 0.000 description 3
230000008436 biogenesis Effects 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000010094 cellular senescence Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000012512 characterization method Methods 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
239000000470 constituent Substances 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000003247 decreasing effect Effects 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
230000002950 deficient Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000009792 diffusion process Methods 0.000 description 3
208000035475 disorder Diseases 0.000 description 3
239000000975 dye Substances 0.000 description 3
239000003974 emollient agent Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
230000012202 endocytosis Effects 0.000 description 3
239000003623 enhancer Substances 0.000 description 3
239000003205 fragrance Substances 0.000 description 3
210000002216 heart Anatomy 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
238000000099 in vitro assay Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
230000031864 metaphase Effects 0.000 description 3
244000005700 microbiome Species 0.000 description 3
239000003068 molecular probe Substances 0.000 description 3
210000004940 nucleus Anatomy 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
230000004792 oxidative damage Effects 0.000 description 3
238000005192 partition Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
150000008104 phosphatidylethanolamines Chemical class 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
229940113116 polyethylene glycol 1000 Drugs 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
238000000159 protein binding assay Methods 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
230000009758 senescence Effects 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
230000032258 transport Effects 0.000 description 3
238000011144 upstream manufacturing Methods 0.000 description 3
239000000080 wetting agent Substances 0.000 description 3
RVLOMLVNNBWRSR-KNIFDHDWSA-N (2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O RVLOMLVNNBWRSR-KNIFDHDWSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 2
208000010444 Acidosis Diseases 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
108010006591 Apoenzymes Proteins 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
108010000912 Egg Proteins Proteins 0.000 description 2
102000002322 Egg Proteins Human genes 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
102000017278 Glutaredoxin Human genes 0.000 description 2
108050005205 Glutaredoxin Proteins 0.000 description 2
108010024636 Glutathione Proteins 0.000 description 2
241000238631 Hexapoda Species 0.000 description 2
101001090065 Homo sapiens Peroxiredoxin-2 Proteins 0.000 description 2
101000619805 Homo sapiens Peroxiredoxin-5, mitochondrial Proteins 0.000 description 2
101001090050 Homo sapiens Thioredoxin-dependent peroxide reductase, mitochondrial Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
101000621749 Penicillium citrinum Peroxiredoxin Pen c 3 Proteins 0.000 description 2
102000003992 Peroxidases Human genes 0.000 description 2
102000013772 Peroxins Human genes 0.000 description 2
108010025366 Peroxins Proteins 0.000 description 2
102100034763 Peroxiredoxin-2 Human genes 0.000 description 2
101710185568 Peroxiredoxin-4 Proteins 0.000 description 2
102100022078 Peroxiredoxin-5, mitochondrial Human genes 0.000 description 2
102100022239 Peroxiredoxin-6 Human genes 0.000 description 2
101710195300 Peroxisomal catalase Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
102000002933 Thioredoxin Human genes 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
208000003486 acatalasia Diseases 0.000 description 2
230000007950 acidosis Effects 0.000 description 2
208000026545 acidosis disease Diseases 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
150000003862 amino acid derivatives Chemical class 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
239000003429 antifungal agent Substances 0.000 description 2
229940121375 antifungal agent Drugs 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
230000021164 cell adhesion Effects 0.000 description 2
230000035567 cellular accumulation Effects 0.000 description 2
229960000541 cetyl alcohol Drugs 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000007957 coemulsifier Substances 0.000 description 2
238000004624 confocal microscopy Methods 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
239000006059 cover glass Substances 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
GNGACRATGGDKBX-UHFFFAOYSA-N dihydroxyacetone phosphate Chemical compound OCC(=O)COP(O)(O)=O GNGACRATGGDKBX-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
239000002612 dispersion medium Substances 0.000 description 2
235000014103 egg white Nutrition 0.000 description 2
210000000969 egg white Anatomy 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
210000003038 endothelium Anatomy 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
235000019197 fats Nutrition 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000003349 gelling agent Substances 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Natural products OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
230000012010 growth Effects 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
208000018875 hypoxemia Diseases 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
239000012133 immunoprecipitate Substances 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000007154 intracellular accumulation Effects 0.000 description 2
230000010189 intracellular transport Effects 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
238000002955 isolation Methods 0.000 description 2
239000007951 isotonicity adjuster Substances 0.000 description 2
229960000448 lactic acid Drugs 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
230000004060 metabolic process Effects 0.000 description 2
239000002207 metabolite Substances 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
210000005063 microvascular endothelium Anatomy 0.000 description 2
239000002480 mineral oil Substances 0.000 description 2
235000010446 mineral oil Nutrition 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000009456 molecular mechanism Effects 0.000 description 2
BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000003883 ointment base Substances 0.000 description 2
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
230000008823 permeabilization Effects 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
235000019271 petrolatum Nutrition 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 2
229920002704 polyhistidine Polymers 0.000 description 2
229920001451 polypropylene glycol Polymers 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
239000002243 precursor Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000001681 protective effect Effects 0.000 description 2
238000009163 protein therapy Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
239000005060 rubber Substances 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
108010048397 seryl-lysyl-leucine Proteins 0.000 description 2
230000019491 signal transduction Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
210000001082 somatic cell Anatomy 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000012360 testing method Methods 0.000 description 2
108060008226 thioredoxin Proteins 0.000 description 2
229940094937 thioredoxin Drugs 0.000 description 2
238000013519 translation Methods 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
239000007762 w/o emulsion Substances 0.000 description 2
238000005406 washing Methods 0.000 description 2
239000001993 wax Substances 0.000 description 2
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
ZWVMLYRJXORSEP-UHFFFAOYSA-N 1,2,6-Hexanetriol Chemical compound OCCCCC(O)CO ZWVMLYRJXORSEP-UHFFFAOYSA-N 0.000 description 1
RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
HLZKNKRTKFSKGZ-UHFFFAOYSA-N 1-Tetradecanol Natural products CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
PCRBTNZNEYJDCH-UHFFFAOYSA-N 1-tetradecoxypropan-2-yl acetate Chemical compound CCCCCCCCCCCCCCOCC(C)OC(C)=O PCRBTNZNEYJDCH-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
XUDRHBPSPAPDJP-UHFFFAOYSA-N 2-[[6-amino-2-[(2-amino-3-hydroxypropanoyl)amino]hexanoyl]amino]-4-methylpentanoic acid Chemical compound CC(C)CC(C(O)=O)NC(=O)C(CCCCN)NC(=O)C(N)CO XUDRHBPSPAPDJP-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
GRXOKLJPWSYWIA-UHFFFAOYSA-N 2-ethylhexyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CC)CCCC GRXOKLJPWSYWIA-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
102100028505 6-pyruvoyl tetrahydrobiopterin synthase Human genes 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010025188 Alcohol oxidase Proteins 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
QJMCHPGWFZZRID-BQBZGAKWSA-N Asn-Lys Chemical class NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O QJMCHPGWFZZRID-BQBZGAKWSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
239000004135 Bone phosphate Substances 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
102000049320 CD36 Human genes 0.000 description 1
108010045374 CD36 Antigens Proteins 0.000 description 1
101100180402 Caenorhabditis elegans jun-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
101710116788 Catalase C Proteins 0.000 description 1
229940123748 Catalase inhibitor Drugs 0.000 description 1
101710188964 Catalase-1 Proteins 0.000 description 1
102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
PXNZYPLSWUTEIE-UHFFFAOYSA-N ClC(CCC)O.C(CCC)O Chemical compound ClC(CCC)O.C(CCC)O PXNZYPLSWUTEIE-UHFFFAOYSA-N 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
230000005778 DNA damage Effects 0.000 description 1
231100000277 DNA damage Toxicity 0.000 description 1
238000013382 DNA quantification Methods 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
230000004568 DNA-binding Effects 0.000 description 1
XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
229920003345 Elvax® Polymers 0.000 description 1
241000283086 Equidae Species 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
241000233866 Fungi Species 0.000 description 1
102000002464 Galactosidases Human genes 0.000 description 1
108010093031 Galactosidases Proteins 0.000 description 1
241000701047 Gallid alphaherpesvirus 2 Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000031448 Genomic Instability Diseases 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
108060003393 Granulin Proteins 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
102000009331 Homeodomain Proteins Human genes 0.000 description 1
108010048671 Homeodomain Proteins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101001090047 Homo sapiens Peroxiredoxin-4 Proteins 0.000 description 1
101000619708 Homo sapiens Peroxiredoxin-6 Proteins 0.000 description 1
108091006905 Human Serum Albumin Proteins 0.000 description 1
102000008100 Human Serum Albumin Human genes 0.000 description 1
101900315094 Human herpesvirus 1 Tegument protein VP22 Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
208000008498 Infantile Refsum disease Diseases 0.000 description 1
125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
101710128836 Large T antigen Proteins 0.000 description 1
241000713666 Lentivirus Species 0.000 description 1
OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
108700026413 Marek's disease virus type 1 UL49 Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
101001090053 Mus musculus Thioredoxin-dependent peroxide reductase, mitochondrial Proteins 0.000 description 1
108010057466 NF-kappa B Proteins 0.000 description 1
102000003945 NF-kappa B Human genes 0.000 description 1
102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
101710083073 NF-kappa-B inhibitor alpha Proteins 0.000 description 1
238000005481 NMR spectroscopy Methods 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
102000001490 Opioid Peptides Human genes 0.000 description 1
108010093625 Opioid Peptides Proteins 0.000 description 1
108010035766 P-Selectin Proteins 0.000 description 1
102100023472 P-selectin Human genes 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
101150056463 PEX5 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
101710126321 Pancreatic trypsin inhibitor Proteins 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108010012822 Peroxiredoxin III Proteins 0.000 description 1
101710185569 Peroxiredoxin-6 Proteins 0.000 description 1
102100026918 Phospholipase A2 Human genes 0.000 description 1
108010058864 Phospholipases A2 Proteins 0.000 description 1
229920001244 Poly(D,L-lactide) Polymers 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
229920001213 Polysorbate 20 Polymers 0.000 description 1
108010084535 ProNectin F Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010019653 Pwo polymerase Proteins 0.000 description 1
239000012083 RIPA buffer Substances 0.000 description 1
108091027981 Response element Proteins 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 1
XUDRHBPSPAPDJP-SRVKXCTJSA-N Ser-Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CO XUDRHBPSPAPDJP-SRVKXCTJSA-N 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010016797 Sickle Hemoglobin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000015125 Sterculia urens Nutrition 0.000 description 1
240000001058 Sterculia urens Species 0.000 description 1
101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
239000005862 Whey Substances 0.000 description 1
102000007544 Whey Proteins Human genes 0.000 description 1
108010046377 Whey Proteins Proteins 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
201000004525 Zellweger Syndrome Diseases 0.000 description 1
208000036813 Zellweger spectrum disease Diseases 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
XLLNINGEDIOQGQ-UHFFFAOYSA-N [acetyloxy(hydroxy)phosphoryl] acetate Chemical compound CC(=O)OP(O)(=O)OC(C)=O XLLNINGEDIOQGQ-UHFFFAOYSA-N 0.000 description 1
239000003070 absorption delaying agent Substances 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
229940099583 aluminum starch octenylsuccinate Drugs 0.000 description 1
229940063655 aluminum stearate Drugs 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
235000013871 bee wax Nutrition 0.000 description 1
239000012166 beeswax Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
150000001602 bicycloalkyls Chemical group 0.000 description 1
230000001588 bifunctional effect Effects 0.000 description 1
239000003613 bile acid Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
238000010256 biochemical assay Methods 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
230000002715 bioenergetic effect Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical class CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
235000014121 butter Nutrition 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229960001631 carbomer Drugs 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
210000003850 cellular structure Anatomy 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
229940099352 cholate Drugs 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
239000004927 clay Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
238000003501 co-culture Methods 0.000 description 1
ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000000490 cosmetic additive Substances 0.000 description 1
230000008878 coupling Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
229940086555 cyclomethicone Drugs 0.000 description 1
230000000093 cytochemical effect Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000005786 degenerative changes Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
239000002781 deodorant agent Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
GUJOJGAPFQRJSV-UHFFFAOYSA-N dialuminum;dioxosilane;oxygen(2-);hydrate Chemical class O.[O-2].[O-2].[O-2].[Al+3].[Al+3].O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O GUJOJGAPFQRJSV-UHFFFAOYSA-N 0.000 description 1
229940100539 dibutyl adipate Drugs 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
229940031578 diisopropyl adipate Drugs 0.000 description 1
MUCZHBLJLSDCSD-UHFFFAOYSA-N diisopropyl fluorophosphate Chemical compound CC(C)OP(F)(=O)OC(C)C MUCZHBLJLSDCSD-UHFFFAOYSA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
230000003467 diminishing effect Effects 0.000 description 1
KWABLUYIOFEZOY-UHFFFAOYSA-N dioctyl butanedioate Chemical compound CCCCCCCCOC(=O)CCC(=O)OCCCCCCCC KWABLUYIOFEZOY-UHFFFAOYSA-N 0.000 description 1
229910001882 dioxygen Inorganic materials 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000007159 enucleation Effects 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
239000005038 ethylene vinyl acetate Substances 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
150000002194 fatty esters Chemical class 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
238000002073 fluorescence micrograph Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
108010021843 fluorescent protein 583 Proteins 0.000 description 1
125000001153 fluoro group Chemical group F* 0.000 description 1
229960005051 fluostigmine Drugs 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
229910021485 fumed silica Inorganic materials 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
229960003180 glutathione Drugs 0.000 description 1
108010086596 glutathione peroxidase GPX1 Proteins 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
230000001744 histochemical effect Effects 0.000 description 1
230000003284 homeostatic effect Effects 0.000 description 1
239000011539 homogenization buffer Substances 0.000 description 1
125000001183 hydrocarbyl group Chemical group 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
230000036737 immune function Effects 0.000 description 1
238000010185 immunofluorescence analysis Methods 0.000 description 1
238000010820 immunofluorescence microscopy Methods 0.000 description 1
238000011532 immunohistochemical staining Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000000865 liniment Substances 0.000 description 1
235000020778 linoleic acid Nutrition 0.000 description 1
OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
239000011344 liquid material Substances 0.000 description 1
201000007270 liver cancer Diseases 0.000 description 1
208000014018 liver neoplasm Diseases 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000018883 loss of balance Diseases 0.000 description 1
239000006210 lotion Substances 0.000 description 1
238000004020 luminiscence type Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000005265 lung cell Anatomy 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000007102 metabolic function Effects 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000002438 mitochondrial effect Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229940043348 myristyl alcohol Drugs 0.000 description 1
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
230000007171 neuropathology Effects 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
238000007899 nucleic acid hybridization Methods 0.000 description 1
230000030648 nucleus localization Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003399 opiate peptide Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000010525 oxidative degradation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
KLAKIAVEMQMVBT-UHFFFAOYSA-N p-hydroxy-phenacyl alcohol Natural products OCC(=O)C1=CC=C(O)C=C1 KLAKIAVEMQMVBT-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
239000010702 perfluoropolyether Substances 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
208000020930 peroxisome biogenesis disorder 1B Diseases 0.000 description 1
230000011597 peroxisome degradation Effects 0.000 description 1
230000005885 phagocytic elimination Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
238000001094 photothermal spectroscopy Methods 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000000049 pigment Substances 0.000 description 1
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
210000003240 portal vein Anatomy 0.000 description 1
230000003244 pro-oxidative effect Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
BFZNCPXNOGIELB-UHFFFAOYSA-N propan-2-yl 10-[5,6-dihexyl-2-(8-oxo-8-propan-2-yloxyoctyl)cyclohex-3-en-1-yl]dec-9-enoate Chemical compound CCCCCCC1C=CC(CCCCCCCC(=O)OC(C)C)C(C=CCCCCCCCC(=O)OC(C)C)C1CCCCCC BFZNCPXNOGIELB-UHFFFAOYSA-N 0.000 description 1
239000003380 propellant Substances 0.000 description 1
229940023566 propylene glycol myristyl ether acetate Drugs 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000007398 protein translocation Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000010791 quenching Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
238000002407 reforming Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000008844 regulatory mechanism Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000008439 repair process Effects 0.000 description 1
230000010410 reperfusion Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000008943 replicative senescence Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000035946 sexual desire Effects 0.000 description 1
238000004904 shortening Methods 0.000 description 1
208000007056 sickle cell anemia Diseases 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
229920002379 silicone rubber Polymers 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
229910021647 smectite Inorganic materials 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011343 solid material Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
239000012128 staining reagent Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
229940012831 stearyl alcohol Drugs 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
108010075210 streptolysin O Proteins 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
230000035882 stress Effects 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010809 targeting technique Methods 0.000 description 1
108091035539 telomere Proteins 0.000 description 1
102000055501 telomere Human genes 0.000 description 1
210000003411 telomere Anatomy 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
230000008719 thickening Effects 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229940033663 thimerosal Drugs 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
210000003014 totipotent stem cell Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000006276 transfer reaction Methods 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000007723 transport mechanism Effects 0.000 description 1
229940108519 trasylol Drugs 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
UYERRXOXXRNFHC-UHFFFAOYSA-N tridodecyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCCCCCC)CC(=O)OCCCCCCCCCCCC UYERRXOXXRNFHC-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000007306 turnover Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
210000003556 vascular endothelial cell Anatomy 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
229940099259 vaseline Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
238000001262 western blot Methods 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

JP2004550263A 2002-10-30 2003-10-30 細胞におけるペルオキシソームカタラーゼ機能の促進 Pending JP2006515168A (ja)